GSK Consumer Healthcare CEO in line to succeed GSK CEO Andrew Witty

LONDON — GSK on Tuesday named Emma Walmsley GSK CEO Designate and successor to Andrew Witty as GSK CEO when he retires on March 31, 2017. She will join the GSK board of directors on Jan. 1, 2017.



"Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare," stated Philip Hampton, GSK chairman. "Under Andrew’s leadership, GSK has successfully developed into a company with market-leading positions in pharmaceuticals, vaccines and consumer healthcare.  These provide excellent platforms for sustainable, long-term growth, and we are confident Emma will successfully build on these strengths.”



“I am delighted and honoured to be appointed GSK’s next CEO," Walmsley said. "GSK is a company that leads both in science and in the way it does business. We have momentum in the Group and as the demand for medical innovation and trusted healthcare products continues to rise, we have the opportunity and the potential to create meaningful benefits for patients, consumers and our shareholders. I’m looking forward to working with Andrew and other leaders over the next few months to ensure a smooth handover and to develop plans for 2017 and beyond.”



Walmsley is currently CEO of GSK's Consumer Healthcare division.



Prior to this, Emma was president of GSK Consumer Healthcare and has been a member of GSK’s corporate executive team since 2011.  Emma joined GSK in 2010 from L’Oreal where, over the course of her 17-year career, she held a variety of marketing and general management roles in the U.K., Europe and U.S. From 2007 she was based in Shanghai as general manager, consumer products for L’Oreal China.